This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Health care stocks were lower Friday, despite a $60 million deal and Corcept's (CORT - Get Report) continued rise.

Boston Scientific (BSX - Get Report) said Thursday after the market's close that it purchased technology for treating symptomatic benign prostatic hyperplasia, or enlarged prostate, from biotechnology company Celsion (CLN). The companies said the purchase regards primarily the Prolieve Thermodilatation System, for which Boston Scientific has been the exclusive distributor since 2004.

Columbia, Md.-based Celsion said Boston Scientific will pay $60 million for the Prolieve assets in three installments, $30 million at the closing of the deal and then $15 million on the first and second anniversaries of the closing. Celsion also said it repaid the principal and accrued interest on a $15 million promissory note due to Boston Scientific at closing.

Boston Scientific was down 23 cents, or 1.4%, to $15.78. Celsion fell 38 cents, or 5.4%, to $6.72.

Corcept Therapeutics shot up another 37 cents, or 21%, to $2.12 Friday, a day after the company bounded 23% after releasing positive proof-of-concept study results on weight-loss drug Corlux. Punk, Zeigel & Co. on Friday upgraded the stock to accumulate from market perform.

Medtronic (MDT - Get Report) on Friday said that it launched a new physician component to its CareLink Therapy Management System for Diabetes. It also announced a new quarterly dividend of 12.5 cents a share for the company's common stock, a 14% increase compared to its prior quarterly dividend of 11 cents a share. The company said the dividend is payable on July 27 to shareholders of record at the close of business on July 6.

In addition, Medtronic is increasing its share repurchase plan by an additional 50 million shares of its common stock, raising the total to 60 million shares. The company said this represented 4.4% of its total common shares outstanding.

And finally, Medtronic elected David Calhoun and Ken Powell to its board of directors. Calhoun is chairman of the board and chief executive of The Nielsen Company. Powell is president, chief operating officer and director of General Mills (GIS - Get Report).

Medtronic closed down 18 cents, or 0.4%, to $51.61.

Johnson and Johnson (JNJ - Get Report) was also down just a bit Friday. On Thursday the company said it received an approvable letter from the Food and Drug Administration for schizophrenia drug Risperdal for adolescents. The letter didn't call for additional study data, just a bit of tinkering with the label, according to the company, which was down $1.38, or 2.2%, to $60.73.

Johnson and Johnson is part of the Amex Pharmaceutical Index, which was down 5.48, or 1.6%, to 344.60 on Friday.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BSX $22.00 0.36%
CORT $5.05 5.87%
GIS $62.22 1.43%
JNJ $112.75 0.60%
MDT $79.35 0.25%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs